Similar articles

Abstract: Objective: Iron deficiency is a common complication in patients with polycythemia vera (PV). hepcidin is a principal regulator of iron homeostasis. The aim of our study was to assess hepcidin%29&ck%5B%5D=abstract&ck%5B%5D=keyword'>prohepcidin, a hepcidin precursor, and other iron status parameters in the serum of PV patients. Methods: The study was performed in 60 patients (F/M 26/34) aged 38~84 (66±10) years. The control group consisted of 20 healthy volunteers, age and sex matched. The following parameters were determined in blood serum samples: hepcidin%29&ck%5B%5D=abstract&ck%5B%5D=keyword'>prohepcidin concentration, iron content, unsaturated iron binding capacity (UIBC), total iron binding capacity (TIBC), transferrin saturation (TfS), and concentrations of ferritin and soluble transferrin receptor (sTfR). Results: All PV patients showed significantly lower levels of hepcidin%29&ck%5B%5D=abstract&ck%5B%5D=keyword'>prohepcidin, higher levels of sTfR and TIBC compared to the control group. 40% of the patients from the study group showed concentrations of ferritin below the normal range and significantly lower levels of serum iron and TfS, and significantly higher levels of sTfR, UIBC and TIBC in comparison with the rest of the study group. In this group of patients, hepcidin%29&ck%5B%5D=abstract&ck%5B%5D=keyword'>prohepcidin concentrations were significantly lower than those in other patients. Conclusion: The results indicate that PV patients suffer from iron metabolism disorders. The decreased serum level of hepcidin%29&ck%5B%5D=abstract&ck%5B%5D=keyword'>prohepcidin in PV patients may be a result of iron deficiency.

[1] Agarwal, M.B., 2007. Clinical applications of molecular haematology: JAK2 in myeloproliferative disorders. J. Assoc. Physicians India, 55:507-510.

[2] Benedict, C., Ghio, A.J., Gehring, H., Schultes, B., Peters, A., Oltmanns, K.M., 2007. Transient hypoxia and downregulation of circulating prohepcidin concentrations in healthy young men. Haematologica, 92(1):125-126.

[3] Birgegard, G., Carlsson, M., Sandhagen, B., Mannting, F., 1984. Does iron deficiency in treated polycythemia vera affect whole blood viscosity? Acta Med. Scand., 216(2):165-169.

[4] Brookes, M.J., Sharma, N.K., Tselepis, C., Iqbal, T.H., 2005. Serum pro-hepcidin: measuring active hepcidin or non-functional precursor? Gut, 54(1):169-170.

[5] Fleming, M.D., 2008. The regulation of hepcidin and its effects on systemic and cellular iron metabolism. Hematology-Am. Soc. Hematol. Educ. Program, 2008:151-158.

[6] Frazer, D.M., Anderson, G.J., 2009. Hepcidin compared with prohepcidin: an absorbing story. Am. J. Clin. Nutr., 89(2):475-476.

[7] Ganz, T., Nemeth, E., 2006. Iron imports. IV. Hepcidin and regulation of body iron metabolism. Am. J. Physiol. Gastrointest. Liver Physiol., 290(2):199-203.

[8] Ganz, T., Olbina, G., Girelli, D., Nemeth, E., Westerman, M., 2008. Immunoassay for human serum hepcidin. Blood, 112(10):4292-4297.

[9] Hutton, R.D., 1979. The effect of iron deficiency on whole blood viscosity in polycythaemic patients. Br. J. Haematol., 43(2):191-199.

[10] Kemna, E., Pickkers, P., Nemeth, E., van der Hoeven, H., Swinkels, D., 2005. Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood, 106(5):1864-1866.

[11] Kemna, E.H., Kartikasari, A.E., van Tits, L.J., Pickkers, P., Tjalsma, H., Swinkels, D.W., 2008. Regulation of hepcidin: insights from biochemical analyses on human serum samples. Blood Cells Mol. Dis., 40(3):339-346.

[12] Kulaksiz, H., Gehrke, S.G., Janetzko, A., Rost, D., Bruckner, T., Kallinowski, B., Stremmel, W., 2004. Pro-hepcidin: expression and cell specific localisation in the liver and its regulation in hereditary haemochromatosis, chronic renal insufficiency, and renal anaemia. Gut, 53(5):735-743.

[13] Mleczko, A., 2004. Owrzodzenie podudzi jako powikłanie stosowania hydroksymocznika u pacjentów leczonych z powodu chorób mieloproliferacyjnych. PDiA, 21(5): 255-259 (in Polish).

[14] Nemeth, E., Ganz, T., 2006. Hepcidin and iron-loading anemias. Haematologica, 91(6):727-732.

[15] Nicolas, G., Chauvet, C., Viatte, L., Danan, J.L., Bigard, X., Devaux, I., Beaumont, C., Kahn, A., Vaulont, S., 2002. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J. Clin. Invest., 110(7):1037-1044.

[16] Pearson, T.C., Grimes, A.J., Slater, N.G., Wetherley-Mein, G., 1981. Viscosity and iron deficiency in treated polycythaemia. Br. J. Haematol., 49(1):123-127.

[17] Pinto, J.P., Ribeiro, S., Pontes, H., Thowfeegu, S., Tosh, D., Carvalho, F., Porto, G., 2008. Erythropoietin mediates hepcidin expression in hepatocytes through EPOR signaling and regulation of C/EBPalpha. Blood, 111(12): 5727-5733.

[18] Piperno, A., Mariani, R., Trombini, P., Girelli, D., 2009. Hepcidin modulation in human diseases: from research to clinic. World J. Gastroenterol., 15(5):538-551.

[19] Rector, W.G., Fortuin, N.J., Conley, C.L., 1982. Non-hematologic effects of chronic iron deficiency: a study of patients with polycythemia vera treated solely with venesections. Medicine, 61(6):382-389.

[20] Roe, M.A., Spinks, C., Heath, A.L., Harvey, L.J., Foxall, R., Wimperis, J., Wolf, C., Fairweather-Tait, S.J., 2007. Serum prohepcidin concentration: no association with iron absorption in healthy men; and no relationship with iron status in men carrying HFE mutations, hereditary haemochromatosis patients undergoing phlebotomy treatment, or pregnant women. Br. J. Nutr., 97(3): 544-549.

[21] Shinzato, T., Abe, K., Furusu, A., Harada, T., Shinzato, K., Miyazaki, M., Kohno, S., 2008. Serum pro-hepcidin level and iron homeostasis in Japanese dialysis patients with erythropoietin (EPO)-resistant anemia. Med. Sci. Monit., 14(9):CR431-CR437.

[22] Spivak, J.L., 2002. Polycythemia vera: myths, mechanisms, and management. Blood, 100(13):4272-4290.

[23] Tefferi, A., 2008. JAK and MPL mutations in myeloid malignancies. Leuk. Lymphoma, 49(3):388-397.

[24] Tefferi, A., Vardiman, J.W., 2008. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and poin-of-care diagnostic algorithms. Leukemia, 22(1):14-22.